



Patent
Attorney Docket No. 033018-121

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of
Frank E. BLONDINO et al.

Application No.: 10/734,150

Filing Date: December 15, 2003

Title: AEROSOL FORMULATIONS AND AEROSOL DELIVERY OF BUSPIRONE, BUPRENORPHINE,
TRIAZOLAM, CYCLOBENZAPRINE AND ZOLPIDEM

Group Art Unit: Unassigned

Examiner: Unassigned

Confirmation No.: Unassigned

**FIRST
INFORMATION DISCLOSURE STATEMENT
TRANSMITTAL LETTER**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Enclosed is a **FIRST** Information Disclosure Statement and accompanying form PTO-1449 for the above-identified patent application.

- ☒ No additional fee for submission of an IDS is required.
- ☐ The fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
- ☐ A statement under 37 C.F.R. § 1.97(e) is also enclosed.
- ☐ A statement under 37 C.F.R. § 1.97(e), and the fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) are also enclosed.
- ☐ Charge _____ to Deposit Account No. 02-4800 for the fee due.
- ☐ A check in the amount of _____ is enclosed for the fee due.

The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

Date: 1-8-04

By

Peter K. Skiff

Registration No. 31,917



In re Patent Application of

Frank E. BLONDINO et al.

Application No.: 10/734,150

Filing Date: December 15, 2003

Group Art Unit: Unassigned

Examiner: Unassigned

Confirmation No.: Unassigned

Title: AEROSOL FORMULATIONS AND AEROSOL DELIVERY OF BUSPIRONE, BUPRENORPHINE, TRIAZOLAM, CYCLOBENZAPRINE AND ZOLPIDEM

**FIRST
INFORMATION DISCLOSURE STATEMENT
TRANSMITTAL LETTER**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Enclosed is a FIRST Information Disclosure Statement and accompanying form PTO-1449 for the above-identified patent application.

- ☒ No additional fee for submission of an IDS is required.
- ☐ The fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
- ☐ A statement under 37 C.F.R. § 1.97(e) is also enclosed.
- ☐ A statement under 37 C.F.R. § 1.97(e), and the fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) are also enclosed.
- ☐ Charge _____ to Deposit Account No. 02-4800 for the fee due.
- ☐ A check in the amount of _____ is enclosed for the fee due.

The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.


Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

Date: 1-8-04

By


Peter K. Skiff

Registration No. 31,917



THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)
)
Frank E. BLONDINO et al.) Group Art Unit:
)
Application No.: 10/734,150) Examiner:
)
Filed: December 15, 2003) Confirmation No.:
)
For: AEROSOL FORMULATIONS AND)
AEROSOL DELIVERY OF BUSPIRONE,)
BUPRENORPHINE, TRIAZOLAM,)
CYCLOBENZAPRINE AND ZOLPIDEM)
)

FIRST INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98.

Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed. However, copies of the listed U.S. patents and U.S. patent application publications are not enclosed since it is no longer required according to the July 11, 2003 waiver of the requirement for copies of cited U.S. patents and U.S. patent application publications in national patent applications filed after June 30, 2003 and international applications entering the national stage under 35 U.S.C. § 371 after June 30, 2003.

The documents are being submitted within three (3) months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later. Since these documents are being filed within the time period set forth in 37 C.F.R. § 1.97(b), no fee or statement is required.

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Date 1-8-04

By: Peter K. Skiff
Peter K. Skiff
Registration No. 31,917

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

FIRST
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number	10/734,150
Filing Date	December 15, 2003
First Named Inventor	Frank E. BLONDINO et al.
Examiner Name	Unassigned
Attorney Docket Number	033018-121

U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)
	5,607,691		Hale et al.	03-04-1997
	5,637,314		Sharpe et al.	06-10-1997
	5,837,280		Kenealy et al.	11-17-1998
	6,228,864	B1	Smith et al.	05-08-2001
	6,231,594	B1	Dae	05-15-2001
	6,312,717	B1	Molinoff et al.	11-06-2001
	6,383,471	B1	Chen et al.	05-07-2002

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	Translation	
					Yes	No

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.